APRILIS 아프릴리스

Development of super bacterial antibiotic resistance diagnostic kit

At the 68th World Health Assembly (WHA) in May 2015, the WHO endorsed the Global Action Plan on Antimicrobial Resistance to tackle antimicrobial resistance (AMR) to address the challenge of AMR, which poses a serious threat to human health. They also launched the Global Antimicrobial Resistance Surveillance System(GLASS), ‘an international antibiotic resistance monitoring system’, for detecting the emergence of new tolerance and international outbreaks as a code of conduct.

To support the humanitarian response of the international community, APRILIS Co., Ltd. successfully developed ‘APRODETE™ CPE-KPC Kit’, a rapid diagnosis kit of carbapenem-resistant Enterobacteriaceae (CRE), which is designated by the WHO’s ranking of a Priority 1 (CRITICAL).

APRILIS Co., Ltd. will continuously promote researching and developing major antibiotic resistance diagnostic kits to become an international R&D company specialized in antibiotic resistance diagnosis.

Development and service of Mobile Healthcare System through Deep Learning

APRILIS ("APRILIS" or "the Company") started as a specialized distributor of Auto-Chek^® blood glucose monitor for home use in 2013. The company is currently developing efficient indicators of chronic disease management. APRILIS is also under the development of contents (diet management, Deep Learning based Multi-Tasking nutrition analysis, glycemic hemoglobin prediction, diabetic complication prediction, etc.), and integrated application system including platform services for home medical devices (blood glucose monitor, blood pressure monitor, body fat analyzer, and smart band).